Prossimo Advisors LLC Makes New Investment in Eli Lilly and Company $LLY

Prossimo Advisors LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, Holdings Channel.com reports. The firm purchased 377 shares of the company’s stock, valued at approximately $294,000.

Several other institutional investors have also bought and sold shares of the business. Laurel Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares during the last quarter. Norges Bank bought a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $8,827,714,000. Nuveen LLC bought a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $4,613,912,000. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after acquiring an additional 765,010 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.7%

LLY opened at $1,074.94 on Monday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The firm has a market cap of $1.02 trillion, a price-to-earnings ratio of 70.26, a PEG ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a fifty day moving average price of $889.37 and a 200-day moving average price of $800.19.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the business posted $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on LLY shares. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Truist Financial lifted their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. CICC Research upped their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Guggenheim reaffirmed a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,047.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.